Esperion Therapeutics (ESPR) Corporate presentation summary

Strategic vision and growth objectives

• Aims to become a global, multi-product pharmaceutical company by 2040, targeting at least five marketed products through internal pipeline advancement and business development.

• Focuses on expanding the bempedoic acid franchise and building a diversified portfolio, including next-generation ACLY inhibitors for rare and orphan diseases.

• Leverages established U.S. commercial infrastructure for acquisitions, co-promotions, and partnerships.

Commercial performance and market opportunity

• Achieved $159.6M in U.S. net product sales in 2025, with 34% year-over-year growth in retail prescription equivalents and a 25% increase in prescriber base.

• Over 70 million U.S. patients are addressable, with a large portion undertreated or not treated for cardiovascular risk.

• Broad payer coverage established, with >90% of commercial and Medicare lives covered.

• Secured ANDA settlements extending market exclusivity, supporting long-term revenue potential.

Product portfolio and pipeline advancement

• Commercialized INNEXLETOL (bempedoic acid) and INNEXLIZET (bempedoic acid/ezetimibe) tablets, with strong adoption among statin-intolerant and resistant patients.

• Advancing triple combination therapies and next-generation ACLY inhibitor ESP-2001 for primary sclerosing cholangitis (PSC).

• Pipeline includes discovery programs targeting chronic kidney disease and other indications.